{"name":"Hepa C","slug":"hepa-c","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMi2gFBVV95cUxPdFVMN2xKOHliRDBjUFBBWUpDRXFWVXg1aEYwV1EzbjlVQl9HTUc4QV8yY24tWExBcnRYVURfNExzeEhoUHZOQTJSVWVKNExhYjFHVlVzbDV3b3VpTVFkelUtMnRnVmt6RHBXLUZITXJVU0xiN1poSkJwMUhsb3ZxYm15SHJ2UW9yQk9lWk43RDZESnJvTXVjNHFwVkkwVzA1aXh1WlRXbGs2ajZFX3hYNTU3WUw4UmduZDh2RFA1QTVSb0JtV0Z0eGladzN3UzByX1llMDN5NjlyUQ?oc=5","date":"2026-01-19","type":"pipeline","source":"Pharmaceutical Technology","summary":"JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens - Pharmaceutical Technology","headline":"JPM26: Atea Pharmaceuticals outlines HCV strategy centred on short-duration regimens","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwgFBVV95cUxOTEVJZVB3UjlXYmxtdXhZWFpTOXJHWXpGRHNObkdjUl9nRUxVVUxTU21ZWHNLU0dvTGtNVjdLbkc0ZHZ2WUYtNjQ4c29iNjI5Q1V1LUY5cTY0dEI2SzdJOUtKM2tLd25iZS0ycC1JSnBDdE1pN3lJRnhuS1hEOWhnMzI5TFU4VU15UzNXNDFTdnBLUnIwMGpOYUxscW4zSFRTbmNkeF9BSVNuLU1VUTV3ODVvem5mOW8xQ3hfRkluNzdfdw?oc=5","date":"2025-12-23","type":"trial","source":"Seeking Alpha","summary":"Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026 - Seeking Alpha","headline":"Atea Pharmaceuticals: Potential Best-In-Class HCV Cure With Pivotal Readouts In 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMimwFBVV95cUxPbDM5bkZwZXBxa2gteEdZdDVmb0J6V0lmeUJEZ0VFT2d3QlpaNkRkLWZoaWJHNFpHejJrN0lpVVpuWlQybDNBS1JsT0F1VVBOenhRbTA3MFdGZHRsb1daaUdrc0ZQdE9MZEdPNVpHQmJXN0k1Rkk3LVZzcm52bjV1WEI5bkpSVzhfTTduUDN1Yi1lMHQ0ZXZsVTBOcw?oc=5","date":"2025-12-22","type":"trial","source":"Yahoo Finance","summary":"Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir and Ruzasvir for Treatment of Hepatitis C Virus - Yahoo Finance","headline":"Atea Pharmaceuticals Completes Patient Enrollment in North American Phase 3 Trial Evaluating Regimen of Bemnifosbuvir an","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMirwFBVV95cUxQZHctQldBQzd1TXkycWN2N0pEUVpQZk9sNmV1Q2VMaTcyc2l3UU1wLUZ6NVVOX0xycHFCVEV6MWZYY29jZ1pGU2g2NTNVU3p5eWpBS1hKODAydEd4cERvNEZ5b09xcUROZ2s0WHdsMjh5VndOTFhJQkkxeXdLVUxydU8yYU55YU9qMDFwQjhwQ1BwTkMwTHg3a1ZxSkhPNzNhLTFVSnkyemVXTVhCTjZn?oc=5","date":"2025-09-12","type":"pipeline","source":"Reuters","summary":"Gilead beats whistleblower lawsuit over hepatitis C drugs - Reuters","headline":"Gilead beats whistleblower lawsuit over hepatitis C drugs","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMivgFBVV95cUxOTHNOQ2pnRVF3TW1UT2l4YlBTakh1eUJnUkFvTjVmNU1udWV0V1Y2bmJTS2N4Z2l5SXF2cHNIVGFPajEzbDR2OVN5R0RRSTU3V1llXzBrcXVXZndTT1J0MV94Sjk1clBVSm12Z3I2OEJKRkp0dWdLS3VMWmpwVnd1RUU4TlNXWllWOWs3VFNpMi1qNDR5Y2tYWWJmaHotWTBiWVVqT3R1dUt4S3I0TTBOdlFlMEVDRGYtaWlFa19B?oc=5","date":"2025-09-12","type":"pipeline","source":"Fierce Pharma","summary":"Gilead prevails in whistleblower lawsuit over alleged hepatitis C prescription kickbacks - Fierce Pharma","headline":"Gilead prevails in whistleblower lawsuit over alleged hepatitis C prescription kickbacks","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiowFBVV95cUxPa2M3eXJpNG95ekpXMEZSTmh6Zmk0ZlNqaV9JSHU4ZHVPQXNySEtTSUF2UlJFai1YM053Q09VOXUxZ0x1TlVEVjM5cTFCczdablB1V3Vfc3RkZ3ByYlFGd2tpaXoteF8zYTU1cjVTbXdKVldGVVpMM0EyMWxLMFdFMHByMFZhV0RjZ0VSMlFaUEhTcENVdzJRZ3VzR2txTy00SHd3?oc=5","date":"2025-08-21","type":"pipeline","source":"pharmaceutical-journal.com","summary":"NHS home testing identifies hundreds with hepatitis C - pharmaceutical-journal.com","headline":"NHS home testing identifies hundreds with hepatitis C - pharmaceutical","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPUTNUVksycDRCZml3NXd1bU1ENmRIMXJWb1FTTlFUOVJzMGs1cXVDakplZGxoVkcwdzluUjE2M1dhMWRnTnNxOFB0bXJBa1JkS3V0akRwU2FEZ1ZyclYwZjlPMFNPNDIzY0gyQ3NfbDN2X3FMY2g0Uy1DZHoyVWE1UVJPUTdEQXN4eG5sQkJiVmx0Wl9SUlhzRWxKNHgtWFQ0X0tPMQ?oc=5","date":"2025-07-22","type":"pipeline","source":"Clinical Leader","summary":"Why Is Hep C Still On The Rise? And What Atea Is Doing About It - Clinical Leader","headline":"Why Is Hep C Still On The Rise? And What Atea Is Doing About It","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisgFBVV95cUxQSGMtdzRPenlmWTVEdDBwbmZlT1l3dDN5T2FEdUNsQ0VOREhyQnllaWNaN3FCWnJWSG53TVh5U1ptckx0eTB2SlA0UlhaTnFXdHBWdExSMVktZDNGT0RRRVZlX2J6QUxpbVNEeW5HaE9jWFlfVkFmcW1VNjdXVEpkQmsyRzVfS3Q4dzl4RlNleG9Rd1QwcmlSem9qcjZFd3k3dzhPbHJsall1YXJGQUotQXN3?oc=5","date":"2025-04-09","type":"trial","source":"eatg.org","summary":"Atea Pharmaceuticals doses first patient in Phase 3 trial for chronic hepatitis C - eatg.org","headline":"Atea Pharmaceuticals doses first patient in Phase 3 trial for chronic hepatitis C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMihAFBVV95cUxNc1JtNExXcHlBd2NDX1lNWUtnX0swZWdkeXh3TjkxTUJSZ1o2aHVSb0dZVG5YeGtTcjB6bmZQWWxvWm9RdmdGRVI1T1lCQ0hmT0t5UGJoR1lMQ3daQ2NVTTAzcVU3UDRHTGNwQW1LM3VOLVpfQXdIV21vVGFfeURzbGJsQU0?oc=5","date":"2025-03-18","type":"pipeline","source":"PharmaTimes","summary":"UKHSA announces new effort to tackle hepatitis C - PharmaTimes","headline":"UKHSA announces new effort to tackle hepatitis C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQU1UyQk1tVVFkVmYwTW5WNHZhNVVvd3JQZF95VlE1Q2NFc0RuNmJEUjVIY1hYektBRzh1ZW5wLXRNaFdfRUtIT2x4X3JkWC1kSk1IS3Y3MjBhWTdSMmR6dEZhT19ObTFPNzUzN0FUZmZDZGtLUXRHVlkySW9SWXBFMGRkMHEwTlBObXlRVkpybw?oc=5","date":"2024-12-04","type":"trial","source":"BioPharma Dive","summary":"Atea plans Phase 3 study for hepatitis C drug after mid-stage results - BioPharma Dive","headline":"Atea plans Phase 3 study for hepatitis C drug after mid-stage results","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinwFBVV95cUxNRF8tTENkNFZUd2xxM0k1eHVSQnFxTVZRSlo5dzcyMG5RcTZ3MzJObHNJMFBnd3BoSFNiNHpTRkhucWlhdmRwTlpyb3NyWnltNFdFdXlnQXFfSklrQ2otZDdFcVd3YVI0OGhyS1VZVGFVNUFJOUdLUWtQMWlQcXdmRzR3Tk9OSC1ZUWxJY2VnYmtYaTlPY1h4ZFBFcDdrZ2M?oc=5","date":"2019-10-25","type":"pipeline","source":"Scientific American","summary":"Pharma Sells States on \"Netflix Model\" to Wipe Out Hep C - Scientific American","headline":"Pharma Sells States on \"Netflix Model\" to Wipe Out Hep C","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxQMXN4R1pVc3NZLWpLTk1JMnE1bkJ1dmpFSHdsM2wtS2hfREpYaWViNHB0aUhZbTh0Sk1WTHd3VHNwNGdJR0FCaEJLRUQ1VkZwdkpuWURtc3c2SWdZRkVYYUUyN1pfbk1BSEwzMm52QWwyeVE1OHdUeW94ZlF1eGlDWXdQQnFQQTJFRnZoR0VhWmpjcnpJM2QzdVpTNkVhQjJkUDNEX1plckdfd3FqWGh3aA?oc=5","date":"2019-08-16","type":"pipeline","source":"USC Schaeffer","summary":"Using the Drug Pricing Netflix Model to Help States Tackle the Hep C Crisis - USC Schaeffer","headline":"Using the Drug Pricing Netflix Model to Help States Tackle the Hep C Crisis","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}